A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of Alzheimer’s disease.

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer’s Disease. For the first time, scientists have developed a drug that works on both major aggregation-promoting ‘hotspots’ of the Tau protein - addressing a critical gap in current treatments.

Researchers say they have sparked an “exciting” breakthrough in treating Alzheimer’s disease by developing a drug to prevent the build-up of toxic proteins in the brain. “This research is taking promising steps towards a new one-of-a-kind therapy which targets tau,

Researchers believe their work will have a significant impact on drug discovery efforts in the field of neurodegenerative diseases.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the development of a new compound that they say is a "promising" candidate in the search for new therapies for neurodegenerative diseases,